Fri, March 18, 2011
Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011

ProPhase Labs to Release Fourth Quarter/Year-End Results on Tuesday, March 15th


//health-fitness.news-articles.net/content/2011/ .. rter-year-end-results-on-tuesday-march-15th.html
Published in Health and Fitness on Wednesday, March 9th 2011 at 7:26 GMT by Market Wire   Print publication without navigation


DOYLESTOWN, PA--(Marketwire - March 9, 2011) - ProPhase Labs (NASDAQ: [ PRPH ]) announced today that financial results for the fiscal 2010 fourth quarter, ended December 31, 2010, will be released before the market opens on Tuesday, March 15, 2011. An earnings conference call will be held later that morning at 11:00 AM. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a Company overview including a review of activities and fourth quarter and year-end results. There will be a question and answer session following initial remarks.

The conference call will be webcast live at [ http://us.meeting-stream.com/prophaselabsinc_031511 ] at 11:00 AM (EDT) on Tuesday, March 15, 2010.

Participants wishing to ask questions may access the live call by dialing (877) 217-6026 Conference ID # 50736554. A replay of the conference call will be available for 90 days on the Company web site at [ www.prophaselabs.com ].

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase's robust OTC distribution channels.

For more information visit us at [ www.ProPhaseLabs.com ].


Publication Contributing Sources